Complex and multifaceted therapy-related myeloid neoplasm following laryngeal cancer treated with Cisplatin and radiotherapy

Therapy-related myeloid neoplasm, usually in the forms of myelodysplastic syndromes/acute myeloid leukemias (t-MDS/AML), are well-known secondary malignancies occurring in cancer patients who received chemo-radiotherapy regimens, especially those including alkylating agents and topoisomerase II inhibitors.1 The leukemogenic potential of other compounds, such as platinum drugs, is less clearly established,2 although a slightly increased risk of secondary AML has been reported after therapy for ovarian3 and testicular4 cancers. We describe the quite rare occurrence of a myelodysplastic/myeloproliferative neoplasm (MDS/MPN) with multiple accumulating genetic anomalies not usually found together as JAK2 V617F, IDH2 R172K and 7q- deletion, after exposure to radiotherapy and platinum based chemotherapeutic agents in a patient treated for laryngeal cancer.